Shionogi マネジメント

マネジメント基準チェック /44

Shionogiの CEO はIsao Teshirogiで、 Apr2008年に任命され、の在任期間は 16.58年です。の年間総報酬は¥ 272.00Mで、 35.3%給与と64.7%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.028%を直接所有しており、その価値は¥ 523.76M 。経営陣と取締役会の平均在任期間はそれぞれ6.6年と5.4年です。

主要情報

Isao Teshirogi

最高経営責任者

JP¥272.0m

報酬総額

CEO給与比率	35.3%
CEO在任期間	16.6yrs
CEOの所有権	0.03%
経営陣の平均在職期間	6.6yrs
取締役会の平均在任期間	5.4yrs

経営陣の近況

Recent updates

Shionogi & Co., Ltd. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next

Oct 30

Shionogi & Co., Ltd. Just Missed EPS By 20%: Here's What Analysts Think Will Happen Next

Jul 31

Shionogi (TSE:4507) Will Pay A Dividend Of ¥85.00

Jul 26

Shionogi (TSE:4507) Will Pay A Dividend Of ¥85.00

Jul 11

Shionogi's (TSE:4507) Soft Earnings Don't Show The Whole Picture

Jun 28

Is Shionogi & Co., Ltd. (TSE:4507) Trading At A 28% Discount?

May 07

Shionogi & Co., Ltd.'s (TSE:4507) Shares May Have Run Too Fast Too Soon

Mar 22

Shionogi (TSE:4507) Will Pay A Dividend Of ¥75.00

Mar 01

CEO報酬分析

Shionogi の収益と比較して、Isao Teshirogi の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	JP¥155b
Jun 30 2024	n/a	n/a	JP¥150b
Mar 31 2024	JP¥272m	JP¥96m	JP¥162b
Dec 31 2023	n/a	n/a	JP¥154b
Sep 30 2023	n/a	n/a	JP¥218b
Jun 30 2023	n/a	n/a	JP¥193b
Mar 31 2023	JP¥291m	JP¥93m	JP¥185b
Dec 31 2022	n/a	n/a	JP¥201b
Sep 30 2022	n/a	n/a	JP¥118b
Jun 30 2022	n/a	n/a	JP¥117b
Mar 31 2022	JP¥244m	JP¥84m	JP¥114b
Dec 31 2021	n/a	n/a	JP¥97b
Sep 30 2021	n/a	n/a	JP¥116b
Jun 30 2021	n/a	n/a	JP¥123b
Mar 31 2021	JP¥241m	JP¥84m	JP¥112b
Dec 31 2020	n/a	n/a	JP¥117b
Sep 30 2020	n/a	n/a	JP¥120b
Jun 30 2020	n/a	n/a	JP¥119b
Mar 31 2020	JP¥160m	JP¥84m	JP¥122b
Dec 31 2019	n/a	n/a	JP¥129b
Sep 30 2019	n/a	n/a	JP¥126b
Jun 30 2019	n/a	n/a	JP¥125b
Mar 31 2019	JP¥198m	JP¥84m	JP¥133b
Dec 31 2018	n/a	n/a	JP¥123b
Sep 30 2018	n/a	n/a	JP¥116b
Jun 30 2018	n/a	n/a	JP¥125b
Mar 31 2018	JP¥160m	JP¥84m	JP¥109b

報酬と市場: Isaoの総報酬 ($USD 1.78M ) は、 JP市場 ($USD 1.40M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Isaoの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Isao Teshirogi (65 yo)

16.6yrs

在職期間

JP¥272,000,000

報酬

Dr. Isao Teshirogi, Ph D., serves as Chairman at Shionogi & Co., Ltd. since July 01, 2022.He is Independent Outside Director at Japan Exchange Group, Inc. since June 19, 2024. Dr. Teshirogi serves as Inde...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Isao Teshirogi	CEO, President & Chairman	16.6yrs	JP¥272.00m	0.028% ¥ 523.8m
Susumu Mitsumori	Vice President of Finance & Accounting Department	2.3yrs	データなし	データなし
Ryuichi Kiyama	Senior Executive Officer & Senior VP of Administration Division	less than a year	データなし	データなし
Takeshi Shiota	Corporate Officer and Senior VP of Corporate Quality Assurance	2.8yrs	データなし	データなし
Yoshimasa Kyokawa	Vice President of Corporate Communications & Secretary Office	6.6yrs	データなし	データなし
Yoshihiro Furuya	Vice President of General Marketing and Compliance Officer of Corporate GXP Compliance Office	8.6yrs	データなし	データなし
Kohji Hanasaki	Senior Executive Officer and Senior VP of Supply Supervisory Unit	7.6yrs	データなし	データなし
John A. Keller	Senior Executive Officer and Senior VP of R&D Supervisory Unit	7.6yrs	データなし	データなし
Kazuhiro Hatanaka	Senior Executive Officer & Senior VP of Corporate Strategy Division	no data	データなし	データなし
Akira Kato	Senior Executive Officer & President of Shionogi Pharma Co.	no data	データなし	データなし
Toshinobu Iwasaki	Senior Executive Officer & Senior VP of Healthcare Business Supervisory Unit	no data	データなし	データなし
Masashi Deguchi	Corporate Officer & Senior VP of DX Promotion Division	2.8yrs	データなし	データなし

6.6yrs

平均在職期間

経験豊富な経営陣: 4507の経営陣は経験豊富で経験豊富です（平均在職期間は6.6年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Isao Teshirogi	CEO, President & Chairman	22.4yrs	JP¥272.00m	0.028% ¥ 523.8m
Hiroshi Ozaki	Independent Outside Director	5.4yrs	データなし	データなし
Tsuguoki Fujinuma	Independent Outside Corporate Auditor	5.4yrs	データなし	0.00035% ¥ 6.5m
Takuko Yamada-Sawada	Vice Chairman of the Board	9.4yrs	JP¥157.00m	0.018% ¥ 334.0m
Shuichi Okuhara	Outside Corporate Auditor	4.4yrs	データなし	データなし
Takaoki Fujiwara	Independent Outside Director	1.4yrs	データなし	データなし
Keiichi Ando	Independent Chairperson of the Board	8.4yrs	データなし	データなし
Akira Okamoto	Standing Corporate Auditor	9.4yrs	データなし	0.0021% ¥ 39.4m
Noriyuki Kishida	Full-time Auditor	less than a year	データなし	0.0021% ¥ 39.4m
Fumi Takatsuki	Independent Outside Director	4.4yrs	データなし	データなし
Yoriko Goto	Outside Corporate Auditor	1.4yrs	データなし	データなし

5.4yrs

平均在職期間

69yo

平均年齢

経験豊富なボード: 4507の取締役会は経験豊富であると考えられます ( 5.4年の平均在任期間)。

Shionogi マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Shionogi & Co., Ltd., Annual General Meeting, Jun 20, 2024

Insufficient new directors

Shionogi & Co., Ltd., Annual General Meeting, Jun 21, 2023

Shionogi Announces Appointment of Corporate Officers, Corporate Reorganization and Personnel Reassignment

Shionogi Announces Appointment of Corporate Officers, Corporate Reorganization and Personnel Reassignment

Recent updates

Shionogi & Co., Ltd. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next

Shionogi & Co., Ltd. to Report Fiscal Year 2025 Results on May 12, 2025

Second quarter 2025 earnings: Revenues exceed analyst expectations

Shionogi & Co., Ltd. Announces Global Phase 3 Trial Demonstrates Post-Exposure Prophylactic Use of Ensitrelvir Prevents Symptomatic COVID-19

Shionogi & Co., Ltd. Announces Dividend for the Second Quarter of Year Ending March 31,2025, Payable on December 2,2024; Provides Dividend Guidance for the Full Year Ending March 31,2025

Shionogi & Co., Ltd. Announces Presents Global Real-World Evidence Study of Cefiderocol Demonstrating Strong Clinical Response Rates Across Seriously III Patients

Shionogi & Co., Ltd. Submits New Drug Application in Japan for Zuranolone as A Treatment for Major Depressive Disorder

New minor risk - Dividend sustainability

Upcoming dividend of JP¥85.00 per share

Shionogi's (TSE:4507) Dividend Will Be ¥85.00

Shionogi & Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2025

Shionogi (TSE:4507) Will Pay A Dividend Of ¥85.00

Shionogi & Co., Ltd. to Report Q2, 2025 Results on Oct 28, 2024

Shionogi's (TSE:4507) Dividend Will Be ¥85.00

Shionogi & Co., Ltd. Just Missed EPS By 20%: Here's What Analysts Think Will Happen Next

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Shionogi (TSE:4507) Will Pay A Dividend Of ¥85.00

Shionogi (TSE:4507) Will Pay A Dividend Of ¥85.00

Final dividend of JP¥85.00 announced

Shionogi's (TSE:4507) Soft Earnings Don't Show The Whole Picture

Full year 2024 earnings: EPS in line with expectations, revenues disappoint

Shionogi & Co., Ltd. to Report Q1, 2025 Results on Jul 29, 2024

Investor sentiment deteriorates as stock falls 15%

Shionogi & Co., Ltd., Annual General Meeting, Jun 20, 2024

Now 21% undervalued

Is Shionogi & Co., Ltd. (TSE:4507) Trading At A 28% Discount?

Shionogi & Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024

Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study (PERSEUS) of Fetroja®/F etcroja® (cefiderocol)

Shionogi & Co., Ltd. to Report Fiscal Year 2024 Results on May 13, 2024

Shionogi & Co., Ltd.'s (TSE:4507) Shares May Have Run Too Fast Too Soon

Upcoming dividend of JP¥75.00 per share

Now 20% undervalued

Shionogi (TSE:4507) Will Pay A Dividend Of ¥75.00

Akili, Inc. Announces Positive Results from Shionogi & Co., Ltd. Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx for Pediatric ADHD Patients in Japan

Now 21% undervalued after recent price drop

Shionogi & Co., Ltd. Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Shionogi & Co., Ltd Announces the Launch of Fetroja(Cefiderocol) Intravenous Infusion 1g Vial in Japan on December 20, 2023

Shionogi & Co., Ltd. Initiation of a Phase 3 Additional Dose Clinical Trial in Japanese Subjects of the Monovalent Vaccine for the XBB1.5 Strain, S-268023

Shionogi & Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Shionogi & Co., Ltd. Presents New Real-World Evidence Demonstrating Effectiveness of Early Treatment with Fetroja®? (Cefiderocol) in Appropriate Patients

Now 21% undervalued

Upcoming dividend of JP¥75.00 per share at 2.3% yield

Shionogi & Co., Ltd. to Report Q2, 2024 Results on Oct 31, 2023

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Shionogi & Co., Ltd. (TSE:4507) announces an Equity Buyback for 12,500,000 shares, representing 4.2% for ¥7,500 million.

Insufficient new directors

Eddingpharm Announces Approval of Mulpleta®? (Lusutrombopag) in China

Shionogi & Co., Ltd. Announces Initiation of a Phase 3 Clinical Trial in Japanese Pediatric Patients of Ensitrelvir for COVID-19

Full year 2023 earnings: EPS exceeds analyst expectations

Now 20% undervalued

Shionogi & Co., Ltd. Enrolls the First Participant in Japan in its Global Phase 3 Trial of Ensitrelvir for the Prevention of Symptomatic SARS-CoV-2 Infection

Shionogi & Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Shionogi & Co., Ltd. Announces Year-End Dividend for the Year Ended March 31, 2023, Payable on June 22, 2023; Provides Dividend Guidance for the End of Second Quarter of Fiscal Year 2024

Shionogi & Co., Ltd., Annual General Meeting, Jun 21, 2023

Now 21% undervalued after recent price drop

Upcoming dividend of JP¥60.00 per share at 2.0% yield

Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Shionogi & Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Shionogi & Co., Ltd. Announces Availability of Innovative Antibiotic, Cefiderocol in Norway

Shionogi & Co., Ltd. Announces Initiation of Phase1/2/3 Clinical Trial (Part 2), Phase 3 Additional Dose Clinical Trial in Japanese Pediatric of the COVID-19 Vaccine, S-268019

Shionogi & Co., Ltd. to Report Q3, 2023 Results on Jan 30, 2023

Shionogi & Co., Ltd. Files for Approval of S-268019, A COVID-19 Recombinant Protein-Based Vaccine, in Japan

Shionogi & Co., Ltd. Announces Tablets 125Mg Approved in Japan for the Treatment of SARS-CoV-2 Infection

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Shionogi & Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2022, Payable on December 1, 2022

マネジメント基準チェック /44